This finding revealed that mTOR activation may be a key resistance mechanism against HDAC inhibitor therapy in liver cancer, suggesting that combining HDACis with mTOR inhibitors could be a promising therapeutic strategy [138]. Here, HDAC9 is linked to liver cancer.